# Rocklatan Retinal Perfusion OCT Study

> **NCT07174401** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Oregon Health and Science University** · enrollment: 30 (estimated)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.
- **DEVICE:** Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.

## Key facts

- **NCT ID:** NCT07174401
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174401, "Rocklatan Retinal Perfusion OCT Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07174401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*